The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Will do Kitzie,
Picked up a report today which gives me confidence that Novacyt will be part of a growing diagnostic industry.
SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infectious Disease Diagnostics - Global Market Trajectory & Analytics".
Global Infectious Disease Diagnostics Market to Reach $20.1 Billion by 2026
Amid the COVID-19 crisis, the global market for Infectious Disease Diagnostics estimated at US$15.8 Billion in the year 2020, is projected to reach a revised size of US$20.1 Billion by 2026
Thanks Kitzie
Site link to Novacyt gives a lot of information on the product lines, not just Covid. You can see these products have been well made and ready for many markets. I plan to take a trip to go and see the stand at the NEC. I would expect many rival bigger players in the market will be also very interested in Novacyt's portfolio of products. This company has a future, the market will eventually catch up with the rise in the SP.
https://www.lab-innovations.com/exhibitor/novacyt-group/
I think this had to come eventually. Balance sheet showing reduced cash position. With this new funding the products can be developed without the worry of running out of cash. The potential market for this type of software is very exciting and could be very profitable. This in turn should see the SP rise.
Below £200M MCAP now. Not many companies out there producing revenue above £100M, 71% gross margins and 43% EBITDA with such a low valuation. Half of that will be the bank balance roughly at the year end? Are we saying this is only worth £100M less cash? Competitors trade a many multiples to us. Be patient, we are a growing company with leading tech. Are we investors or traders?
No wonder they were short on votes, Barclays sent me their corporate action notice after the cut off date to vote? Many shareholder's will hold their shares with the likes of Barclays, so if this was repeated across several brokers you can see why there were only a small amount of votes.
Take a look at the RNS from EKF Diagnostics today. Their acquisition of Advanced Diagnostic Laboratory today gives me the confidence that Novacyt is under valued. They have a £373M Mcap against ours of £211M. Their revenues are a lot smaller than ours in the same field. Let's get the new man in charge and hopefully we can turn a corner.
Tough time for many here. What keeps me invested is the low Market Cap £208M against the fundamentals. The enterprise value of the business is £130M approx currently taking out cash. This is very low for the IP, Assets, Goodwill of the business and future profits in a growing sector of business. P/E is very low even taking out dispute figures. It will become a takeover target if the SP remains at this level. Payback for takeover buyer would be very short in term of years. Be patient.
Quite right Kitzie, why would posters be here wasting time trying to deramp a share? Only reason is to get shares cheap! Paid derampers can be spotted a mile off.
Diagnostics is prime industry, especially with test innovation here....NCYT will certainly be seen a T/O target....not many AIM stocks with these fundamentals out there.....I see many (on this board too) trying to shake many invested.
Not even making any money and look at the valuation? Paid posters clearly out today, can spot them a mile off.
Oxford Nanopore announces London IPO after hitting $3.3 bln valuation.Sept 9 - Oxford Nanopore, a provider of rapid COVID-19 tests to Britain's national health service, announced a London listing on Thursday as it aims to build on the 2.4 billion pound ($3.3 billion) valuation it achieved in its latest funding round.
The life sciences company is planning a free float of at least 25% of its shares in the initial public offering (IPO) and said it was aiming to reduce its losses to breakeven in the next five years.
Take a look at EKF half year results today. A diagnostics company with a market cap of 364 Million against Novacyt's 254 Million. They trade at a P/E of 32.65 against Novacyt's at 1.77 . Take a look at their figures, a conservative look shows they are a 1/3 the size of Novacyt presently. I'm confident our MCAP will be worth a lot more by year end.